- Home
- SERA vs LUNG Comparison
SERA vs LUNG Comparison
Compare SERA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERA
- LUNG
- Stock Information
- Founded
- SERA 2008
- LUNG 1995
- Country
- SERA United States
- LUNG United States
- Employees
- SERA N/A
- LUNG N/A
- Industry
- SERA Precision Instruments
- LUNG Industrial Specialties
- Sector
- SERA Health Care
- LUNG Health Care
- Exchange
- SERA Nasdaq
- LUNG Nasdaq
- Market Cap
- SERA 258.3M
- LUNG 248.0M
- IPO Year
- SERA 2021
- LUNG 2020
- Fundamental
- Price
- SERA $6.29
- LUNG $6.62
- Analyst Decision
- SERA
- LUNG Strong Buy
- Analyst Count
- SERA 0
- LUNG 7
- Target Price
- SERA N/A
- LUNG $13.71
- AVG Volume (30 Days)
- SERA 135.2K
- LUNG 225.1K
- Earning Date
- SERA 11-06-2024
- LUNG 10-28-2024
- Dividend Yield
- SERA N/A
- LUNG N/A
- EPS Growth
- SERA N/A
- LUNG N/A
- EPS
- SERA N/A
- LUNG N/A
- Revenue
- SERA $107,000.00
- LUNG $76,583,000.00
- Revenue This Year
- SERA N/A
- LUNG $22.73
- Revenue Next Year
- SERA $2,020.00
- LUNG $19.02
- P/E Ratio
- SERA N/A
- LUNG N/A
- Revenue Growth
- SERA N/A
- LUNG 26.26
- 52 Week Low
- SERA $1.56
- LUNG $5.46
- 52 Week High
- SERA $12.36
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- SERA 39.99
- LUNG 32.18
- Support Level
- SERA $6.87
- LUNG $6.56
- Resistance Level
- SERA $7.27
- LUNG $7.47
- Average True Range (ATR)
- SERA 0.48
- LUNG 0.37
- MACD
- SERA -0.10
- LUNG -0.22
- Stochastic Oscillator
- SERA 0.00
- LUNG 1.83
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.